Neuren Pharmaceuticals (ASX:NEU) started the development of NNZ-2591 for the potential treatment of hypoxic-ischemic encephalopathy (HIE), according to a Thursday filing with the Australian bourse.
HIE is a type of brain injury resulting from inadequate oxygen or blood flow in a baby's brain before or shortly after birth, the filing said.
The company aims for a pre-investigational new drug meeting with the US Food and Drug Administration in the fourth quarter of the year before initiating a clinical trial in patients with HIE, per the filing.
Shares were up 3% in morning trade Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.